References
- Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44.
- Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–2466.
- Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458.
- Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197.
- Manji S. (s_r). There are so many biologics!! What do you pick? Mepolizumab, reslizumab, benralizumab and dupilumab! Dear drug companies, how about a head to head?” 2018;18:13. Twitter.
- Peyrin-Biroulet L, Lopez A, Sandborn W. Head-to-head comparative studies: challenges and opportunities? J Crohns Colitis. 2017;11(suppl_2):S567–S575. Volume Issue 1 March Pages https://doi.org/https://doi.org/10.1093/ecco-jcc/jjw167.